By Michael Calia
Medtronic Inc. (MDT) on Tuesday said it had settled a
long-running patent dispute with Edwards Lifesciences Corp.
(EW).
The company also reported a big drop in fiscal fourth-quarter
earnings because of charges for the settlement of lawsuits.
Medtronic said it would pay Edwards $750 million and royalty
payments through April 2022 over sales of its CoreValve, an
artificial aortic heart valve.
The settlement comes weeks after a federal appeals court delayed
an injunction against sales of CoreValve, dragging out a dispute
that had lasted several years. In 2010, a jury found that CoreValve
infringed upon an Edwards patent.
The companies dismissed all pending litigation, and neither
admitted their products infringe any of the other company's
patents.
Also on Tuesday, Metronic posted a profit of $448 million, or 44
cents a share, for the fiscal fourth quarter ended April 25, down
from $969 million, or 95 cents a share, a year earlier. Excluding a
charge related to the Edwards settlement, as well as a charge
related to a product liability lawsuit, per-share earnings were
$1.12, up from $1.10 in the prior-year period.
Revenue improved 2.4% to $4.57 billion. Excluding currency
fluctuations, revenue rose 3%.
Analysts polled by Thomson Reuters expected profit of $1.12 a
share and revenue of $4.58 billion.
The company earlier this month said it would post a charge of
$120 million-$140 million to resolve a product liability lawsuit
relating to its Infuse bone graft.
Medtronic on Tuesday also said it expected full-year revenue
growth of 3% to 5% on a constant-currency basis, with per-share
earnings of $4 to $4.10. Analysts polled by Thomson Reuters had
been expecting revenue growth of 4% and per-share earnings of
$4.09.
Write to Michael Calia at michael.calia@wsj.com
Access Investor Kit for Edwards Lifesciences Corp.
Visit
http://www.companyspotlight.com/partner?cp_code=A591&isin=US28176E1082
Access Investor Kit for Medtronic, Inc.
Visit
http://www.companyspotlight.com/partner?cp_code=A591&isin=US5850551061
Subscribe to WSJ: http://online.wsj.com?mod=djnwires